Laurus Labs makes the active ingredients inside medicines, and increasingly makes medicines to order for other drug companies. It began in HIV treatments and still supplies them, but the faster-growing half of the business is contract development and manufacturing — taking a customer's molecule from laboratory to commercial scale. It runs 15 manufacturing sites and employs 8,126 people, more than 1,540 of them scientists. It is good at it by the numbers that matter here: a 26.2% operating margin and 18.0% return on capital, both roughly double where they sat a year earlier.
Yes, on the measures a contract manufacturer is judged by — and the half everyone calls the old business is not standing still either. Contract manufacturing revenue was ₹835 crore in the June quarter on the small-molecule side, up 69%, with a further ₹35 crore from the biotechnology arm. Together 43% of the company, drawn from more than 125 active customer projects. The other half is more interesting than it looks. Affordable medicines turned over ₹1,156 crore, up 10%, led by finished dosage forms. Inside it, the antiretroviral line that founded this company grew 3% to ₹669 crore. So the mature part is flat and the division around it is not. Regulatory standing is the third measure, and it is strong: 54 successful inspections by the American, WHO, European and Japanese regulators, 92 drug master files, and 96 finished-product dossiers with two more filed in the quarter. On the risk a reader would assume — that a handful of customers carry it — management was asked directly and said there is no meaningful concentration by programme, customer or therapeutic area, and that within contract manufacturing the work is predominantly on-patent innovator molecules.
No, not any more. Debt-to-equity is 0.48, with borrowings of ₹2,518 crore against ₹114 crore of cash and ₹5,300 crore of shareholders' funds. Net debt is now 1.3 times annual operating profit, against 3.1 times two years ago — the borrowings barely moved, but the profit they are measured against more than doubled.
Laurus Labs is converting a shift in its sales mix into much higher margins. Contract manufacturing grew 69% in the June quarter and now makes up 43% of revenue, lifting operating margin to 31.8% from 24.8% a year earlier. It put 19% of that quarter's revenue into new plants — ₹1,070 crore, or 16% of revenue, across the full year — while still collecting cash.
Growing again, after two years of not growing. Revenue was ₹2,026 crore in the June quarter, up 29%, and ₹6,813 crore last year, up 22.7%, with profit up 148% to ₹889 crore. But revenue three years ago was ₹6,041 crore, so the company has added only 4.1% a year over that period — this is a recovery to an old peak rather than a climb past it.
Almost entirely on its own. It spent ₹394 crore on plants in the June quarter, 19% of revenue, and more than ₹4,700 crore over five years, of which over 85% went to growth rather than maintenance. New sites are under construction at Vizag and a joint venture plant with KRKA is being built at Hyderabad. The only outside addition was a development and commercial agreement with Aarvik Therapeutics covering two clinical-stage antibody-drug conjugates for the Indian market.
Improving sharply. Operating margin reached 31.8% in the June quarter, 7.0 percentage points higher than a year earlier, and gross margin 62.7%, up 3.3 points. For the full year, operating margin was 26.2% against 19.0%. The gain comes from selling more contract manufacturing, which earns more than generics.
Much more than a year ago. Return on capital rose to 18.0% from 10.1%, and return on equity to 16.8% from 8.0%. On how hard the factories work, management sets its own bar at an asset turnover ratio a little above 1.0, and says plainly that the company is not there yet — the newest plants are not earning their keep.
Yes, comfortably. It generated ₹1,624 crore of cash from operations against ₹889 crore of reported profit, and over three years has collected roughly twice its profit in cash. It now takes 115 days to get paid, down from 132.
Laurus Labs was founded and is run by Dr. Satyanarayana Chava, its chief executive, with V.V. Ravi Kumar as finance director. In April 2024 two more members of the founder's family, Krishna Chaitanya Chava and Soumya Chava, joined as executive directors — so three of the five executive seats belong to one family, which holds about 23.3% of the shares within a promoter group owning 27.47%.
The auditors, Deloitte Haskins & Sells LLP, signed off with no objections, no qualifications and no matters they wanted to draw attention to. For a company of this size, a Big Four signature with nothing attached is worth more than it sounds.
Laurus Labs sells in two halves, and is quietly buying the ground for a third. Affordable medicines — active ingredients and finished tablets, largely for HIV — were 57% of June-quarter revenue at ₹1,156 crore. Contract manufacturing for other drug companies was 43%, at ₹835 crore on small molecules plus ₹35 crore from a biotechnology arm using fermentation and biocatalysis. What sets it apart is using an established, slow-growing medicines business to fund a contract arm growing at 69%. And what it is building next is visible in three things announced this quarter: a development and commercial agreement with Aarvik Therapeutics for two clinical-stage antibody-drug conjugate molecules for India, a big pharma client onboarded with what the founder called "significant opportunities ahead of us", and the final handover of more than 500 acres of land from the Andhra Pradesh government. Antibody-drug conjugates and gene therapy are named investment areas — Laurus is the only company covered here in the latter.
Divi's Laboratories, Syngene International, Anthem Biosciences, Piramal Pharma, Sai Life Sciences, Neuland Laboratories and Cohance Lifesciences are the main listed Indian rivals — Divi's, the largest, on half as much revenue again as Laurus. In affordable HIV medicines it competes with Aurobindo, Cipla and Hetero, which is a different fight: those are volume businesses won on cost.
Three things are going right: a contract book growing 69%, a margin that moved seven points in a year, and two agreements signed this quarter that do not show up in any number yet. Contract manufacturing reached ₹835 crore in the June quarter, up 69%, across more than 125 active projects, with operating margin at 31.8% against 24.8% a year earlier and gross margin at 62.7%. Research spending rose 70% to ₹118 crore — 5.8% of revenue — explicitly to build gene therapy and antibody-drug conjugate capability. New this quarter: the Aarvik Therapeutics agreement for two clinical-stage conjugates, and a big pharma client onboarded. Against it: the antiretroviral line that built the company grew 3%, and while the wider affordable medicines division grew 10%, that is a mature business funding an ambitious one. The 500-acre land handover and the 400-kilolitre fermentation plant due by the end of this year are capital going out well before revenue comes in. And the reassurance worth recording, because it is the risk every reader assumes: asked directly about concentration, management said there is none of consequence by programme, customer or therapy — and that contract work is predominantly on-patent innovator molecules rather than commodity supply.
Two halves, two different cycles. Contract manufacturing follows Western drug pipelines — demand tied to customers' research spending rather than consumer cycles, though a customer's failed trial can remove a revenue line at short notice. The HIV half is mature rather than cyclical: it grew 3% in the June quarter while contract manufacturing grew 69%.
Laurus Labs is priced for the recovery to continue. The share had more than doubled in the year to 17 August 2026 and carried one of the higher ratings in Indian pharmaceuticals. Institutions have been buying steadily for three years while public shareholders have sold.
Expensive on every measure. At ₹1,809.70 on 17 August 2026 the share was priced at 110 times earnings, 18.4 times book value and 14.3 times sales, on FY26 earnings of ₹16.46 a share and a market value of ₹97,706 crore. On earnings that was dearer than either Divi's Laboratories, at 88 times its last full year, or Syngene International at 51 — though on sales Laurus at 14.3 times sat below Divi's 21.3. Set against growth it is steeper still: profit has compounded at 4% over three years, putting the price-to-earnings-growth ratio near 27.
Bought. Foreign funds have risen from 24.0% to 28.0% over three years and Indian funds from 11.0% to 13.7%, taking institutions together from 35.0% to 41.7%. Public shareholders — everyone outside the promoters and the institutions — fell from 37.8% to 30.8%, and the number of shareholders dropped from 4.03 lakh to 2.92 lakh. The sharpest move was the June quarter, when foreign funds went from 25.8% to 28.0%.
Seven investors own more than 1%, on the June 2026 register. The largest are Mirae Asset Large & Midcap Fund at 4.33% and Capital Group's New World Fund at 4.28%, followed by Anukar Projects at 3.24% and Smallcap World Fund at 2.77%. The individual investor Akash Bhanshali holds 1.32%.
It is doing none of the three in any large way. The share count has risen 0.6% over five years, so existing holders have not been diluted. Borrowings fell from ₹2,764 crore to ₹2,518 crore. It pays a dividend of ₹2 a share, about 12% of profit.
A sector, read end to end, and the companies as they are published. Roughly monthly. Nothing else, and one click to stop.
Loading…